Ivacaftor: A review of its use in patients with cystic fibrosis

Drugs

Volumn 73, Issue 14, 2013, Pages 1595-1604

  Deeks, Emma D ^a  

^a Adis   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; IVACAFTOR;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CHLORIDE TRANSPORT; CYSTIC FIBROSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEMOPTYSIS; HUMAN; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; NOSE OBSTRUCTION; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; SEVERE HEPATIC IMPAIRMENT; SEVERE RENAL IMPAIRMENT; SINUS CONGESTION; UPPER RESPIRATORY TRACT INFECTION;

AMINOPHENOLS; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; HUMANS; QUINOLONES;

EID: 84897556769     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0115-2     Document Type: Review

References (37)

1. Pettit RS. Cystic fibrosis transmembrane conductance regulatormodifying medications: the future of cystic fibrosis treatment. Ann Pharmacother. 2012;46(7-8):1065-75
2. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891- 904
3. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest. 2011;139(6):1480-90
4. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care. 2009;54(5):595-605
5. European Medicines Agency. Assessment report: Kalydeco (ivacaftor). 2012. http://www. ema. europa. eu/docs/en-GB/document- library/EPAR-Public- assessment-report/human/002494/WC5001 30766. pdf (Accessed 21 Aug 2013)
6. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35(3):246-59
7. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-9
8. Cystic Fibrosis Trust. Standards for the clinical care of children and adults with cystic fibrosis in the UK; 2011. http://www. cftrust. org. uk/aboutcf/publications/consensusdoc/CF-Trust-Stan dards-of-Care-2011- %28website-Apr-12%29. pdf (Accessed 21 Aug 2013)
9. EuropeanMedicinesAgency. Kalydeco 150 mgfilm-coated tablets: summary of product characteristics; 2013. http://www. ema. europa. eu/docs/en-GB/document- library/EPAR-Product-Information/ human/002494/WC500130696. pdf (Accessed 21 Aug 2013)
10. US Food and Drug Administration. Kalydeco (ivacaftor) tablets: US prescribing information; 2012. http://www. accessdata. fda. gov/ drugsatfda-docs/label/2012/203188s001lbl. pdf (Accessed 21 Aug 2013)
11. Eckford PDW, Li C, Ramjeesingh M, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287(44):36639-49
12. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825-30
13. Yu H, Burton B, Huang C-J, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237-45
14. Woodworth BA, Zhang S, Skinner D, et al. Comparison of CFTR and ciliary beat frequency activation by the CFTR modulators VX-770, VRT532, and UCCF-152 in primary sinonasal epithelial cultures [abstract no. 114]. Pediatr Pulmonol. 2011;46:251-2
15. Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013;110(11):4404-9
16. VanGoor F,YuH,BurtonB, et al. Effect of ivacaftor onCFTRforms with missensemutations associatedwith defects in protein processing or function. J Cyst Fibros. 2013. doi:10. 1016/j. jcf. 2013. 06. 008
17. Pohl K, Reeves EP, McElvaney NG. The CFTR potentiator ivacaftor corrects defective degranulation of secondary and tertiary granules by cystic fibrosis neutrophils [abstract no. WS9. 9]. J Cyst Fibros. 2012;11(Suppl. 1):S21
18. Davies JC, Sheridan H, Lee P, et al. Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease [abstract no. 249]. Pediatr Pulmonol. 2012;47:311
19. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003
20. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-72 (plus supplementary appendix)
21. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-25 (plus supplementary appendix)
22. Altes T, Johnson MA, Miller GW, et al. Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D-CFTR mutation [abstract no. 196]. Pediatr Pulmonol. 2012;47:291
23. Li C, Song T, Ordonez C, et al. No effect of therapeutic and supratherapeutic doses of ivacaftor on QTc interval in healthy subjects [abstract no. PII-66]. Clin Pharmacol Ther. 2013;93(S1):S76
24. Hayes E, Pohl K, McElvaney NG, et al. The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz). 2011;59(2):97-112
25. Zha J, Zhang J, Ordonez C. Pharmacokinetics (PK), metabolism and excretion of [14C] VX-770, a potentiator of cystic fibrosis transmembrane conductance regulator (CFTR), in healthy subjects [abstract no. 1124131]. J Clin Pharmacol. 2011;51(9):1358-9
26. Zha J, Kumor K, Zhang J, et al. Exposure-response relationship for FEV1 and sweat chloride in patients with cystic fibrosis treated with ivacaftor, a CFTR potentiator [abstract no. 235]. Pediatr Pulmonol. 2012;47:306
27. Zha J, Zhang J, Ordonez C, et al. Clinical pharmacology profile of ivacaftor, a CFTR potentiator [abstract no. 236]. Pediatr Pulmonol. 2012;47:306-7
28. Vertex Pharmaceuticals Incorporated. Study of ivacaftor in cystic fibrosis subjects aged 12 years and older with the G551D mutation (STRIVE) [ClinicalTrials. gov identifier NCT00909532]. US National Institutes of Health, ClinicalTrials. gov; 2013. http:// www. clinicaltrials. gov (Accessed 21 Aug 2013)
29. Vertex Pharmaceuticals Incorporated. Study of ivacaftor in cystic fibrosis subjects aged 6 to 11 years with the G551D mutation (ENVISION) [ClinicalTrials. gov identifier NCT00909727]. US National Institutes of Health, ClinicalTrials. gov; 2012. http:// www. clinicaltrials. gov (Accessed 21 Aug 2013)
30. McKone E, Li H, Gilmartin G, et al. Long-term safety and efficacy of ivacaftor in persons with cystic fibrosis who have the G551D-CFTR mutation [abstract no. 211]. Pediatr Pulmonol. 2012;47(S35):296-7
31. Quittner A, Ramsey B, Rodriguez S, et al. Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract no. 212]. Pediatr Pulmonol. 2012;47:297
32. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258-64
33. US National Institutes of Health. ClinicalTrials. gov; 2013. http:// www. clinicaltrials. gov (Accessed 21 Aug 2013)
34. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718-24
35. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179-96
36. Boyle MP, Bell S, Konstan M, et al. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508DEL homozygous patients: phase II study results [abstract no. 260]. Pediatr Pulmonol. 2012;47:315
37. Boyle MP, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation [abstract no. 212]. Pediatr Pulmonol. 2011;46:287.